HEPA Hepion Pharmaceuticals Inc.

Biotech Analyst Ratings

Latest News

1. 03 May 2022 Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial

   - HepQuant Evaluation Offers Sensitive Measurement of Hepatic Function and Correlation with Clinical Outcomes -
   

   - Dedicated Phase 2b Trial Supports Overarching NASH Program for Rencofilstat -

   - Four-Month, Three Arm Trial will Inform on Numerous NASH Functional Biomarkers -

   EDISON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), Hepatocellular Carcinoma ("HCC"), and other chronic liver diseases, today announced that it has entered into a clinical collaboration with HepQuant, a Denver-based, privately held company with novel…

   View Full Article
2. 07 March 2022 Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference

   EDISON, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and hepatocellular carcinoma ("HCC"), announced today that its CMO, Dr. Todd Hobbs, will present at the Q1 Investor Summit Conference on Wednesday, March 9, 2022 at 1:15 p.m. Eastern Time.
   

   The virtual presentation will be broadcast live and archived on the Company's website at www.hepionpharma.com under "Events" in the "Investors" section.

   About Hepion Pharmaceuticals

   The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins…

   View Full Article
3. 15 February 2022 Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Company's Strategic Medical Affairs in Asia

   - Dr. Cheung, who has dedicated his career to NASH, hepatocellular carcinoma, fatty liver disease, and viral hepatitis will endeavor to advance Hepion's business development and partnering efforts in Asia -
   

   EDISON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and hepatocellular carcinoma ("HCC"), today announced that it has appointed Eddie C. Cheung, M.D., FACG, to lead Strategic Medical Affairs in Asia.  
   

   In this newly created role with Hepion, Dr. Cheung will explore and identify possible partnerships, and will liaise with…

   View Full Article
4. 14 February 2022 Hepion Pharmaceuticals to Present at BIO CEO & Investor Conference

   EDISON, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and hepatocellular carcinoma ("HCC"), announced today that its CEO, Dr. Robert Foster, will present a corporate overview at the BIO CEO & Investor Conference on Tuesday, Feburary 15, 2022 at 11:15 a.m. Eastern Time at the New York Marriott Marquis.
   

   The Company's live presentation will be made available through the BIO CEO & Investor Conference website and available on-demand to registered participants during the conference at https://www.bio.org/events/bio-ceo-investor-conference/sessions…

   View Full Article
5. 26 January 2022 Hepion Pharmaceuticals' Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study

   EDISON, N.J., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and hepatocellular carcinoma ("HCC"), today announced the results of a nonclinical research study showing that its clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor growth and extended mouse survival when combined with an anti-PD1 antibody, an immune checkpoint inhibitor ("ICI"). The effects were observed in fatty livers, which may be associated with lower anti-PD1 efficacy in HCC, suggesting that rencofilstat may increase the treatment…

   View Full Article